Search Results
Your search for ,loW matches 7101 pages
Showing 1 - 50Can AI Provide an ‘Early Alert’ for Breast Cancer Before Diagnosis?
Three commercially available radiology artificial intelligence (AI) systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to a Swedish study published by Hickman et al in Radiology. In a retrospective study, researchers tested three...
Coming Out in the Exam Room
Preparing for a patient I was going to see in breast oncology clinic, I noticed she was single and that her partner was female. The information system at the hospital I was working in included a patient photograph along with the usual demographic and clinical information. The photograph had caught ...
Prostate Cancer Screening Controversies
We read with interest the recent commentary by Derek Raghavan, MD, PhD, FACP, FASCO, FRACP, on ‘Prostate Screening Saved My Life’ Is That Really True in Most Cases?’ (The ASCO Post, April 25, 2026).1 As patient advocates, we agree with Dr. Raghavan on one important point: simplistic claims such as...
Advancing Clinical Trials and Decision-Making With Synthetic Real-World Data
Synthetic real-world data generated by AI can model treatment patterns and clinical outcomes across large patient cohorts while accelerating clinical trials and drug development, according to Eddy Saad, MD, MSc, a Research Fellow in Medicine at Dana-Farber Cancer Institute. During a presentation...
ASCO Updates Policy Statement on 340B Drug Pricing Program
Early last month ASCO published an updated policy statement on the 340B Drug Pricing Program in JCO Oncology Practice.1 The update proposes a package of recommendations to expand practice eligibility, address potential abuses, and ensure the 340B program benefits the patients it was intended to...
‘The Science and Practice of Translation: Improving Cancer Outcomes Worldwide’
“Good morning, and welcome to the 62nd Annual Meeting of ASCO! ¡Buenos días, y bienvenidos a la sexagésima segunda reunión anual de ASCO! This is the world’s largest cancer research conference and the premier global platform for oncology innovation! But what brings us together today is not just...
Review of Breast Cancer News and Studies
Among the high-quality abstract presentations at ASCO and the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. The ASCO Post asked its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his selection and thoughts on some...
Weighing the Evidence Supporting Aspirin vs GLP-1RAs in Colorectal Cancer Prevention
A study by Jones et al offers a provocative contribution to the landscape of colorectal cancerprevention by directly comparing two pharmacologic strategies with markedly different historical roles in prevention (see sidebar on page 47).1 Aspirin has long served as the benchmark for primary...
A Burning Question: Can Wildfire Smoke Drive Cancer Risk?
Exposure to wildfire smoke was associated with significantly elevated risks of several cancers, including lung, colorectal, breast, bladder, and blood cancers, according to evidence from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial presented in a poster and press...
Geriatric Assessment Is the Future: Retiring Karnofsky and ECOG Performance Status in Modern Cancer Care
The purpose of this editorial is to challenge the continued reliance on Karnofsky Performance Status and Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status as primary tools for evaluating older adults with cancer. These measures have been in oncology practice for decades and...
Early Study Finds Intralesional PD-1 Blockade ‘Promising’ for Oral Cancer Prevention
Intralesional nivolumab reduced the size of precancerous lesions and preserved quality of life in patients with oral epithelial dysplasia, according to results from a first-in-human phase I dose-escalation trial presented in a poster and press briefing during the 2026 American Association for...
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer
Four-year follow-up from the phase III RUBY clinical trial showed durable long-term benefit with front-line dostarlimab-gxly, a PD-1 blocker, plus carboplatin/paclitaxel in patients with mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) primary advanced or recurrent endometrial ...
New Research Links Low Alcohol Consumption to Elevated Health Risks
Researchers reported there was no protective net effect of any level of alcohol consumption on health observed in a new study published by George et al in the Journal of Studies on Alcohol and Drugs. Further, researchers reported that low levels of alcohol use may be associated with elevated health ...
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma...
AML: All-Oral Regimen Safe and Eases Treatment Administration Burden
An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine....
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response?
A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Results were presented at the 2026 ASCO Annual Meeting (Abstract 2580). “This is really a cautionary...
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO...
Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
According to findings from a phase III trial presented at the 2026 ASCO Annual Meeting (Abstract LBA6007), a low-cost regimen combining triple oral metronomic chemotherapy with ultra-low-dose immunotherapy significantly improved survival and reduced toxicity compared with platinum-based...
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) for first-line treatment can reduce tumor progression in patients with aggressive diffuse large B-cell lymphoma...
Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC
The phase III LIBRETTO-432 trial of adjuvant therapy with the central nervous system (CNS)–penetrant oral RET inhibitor selpercatinib met its primary endpoint of improved event-free survival in patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC), based on data presented ...
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in patients with advanced...
Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL
Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and...
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
In 2016, The ASCO Post published an article titled “An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix,” highlighting the work of Robert D. Hilgers, MD—now deceased—and the Women’s Global Cancer Alliance (WGCA) in building a cervical cancer screening and prevention program in...
Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions
Two larger doses of radiotherapy for prostate cancer caused no additional side effects compared to the standard five doses of radiotherapy, according to results from the HERMES trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the...
I Have Advanced-Stage Lung Cancer. I Refuse to Be a Victim of the Disease
I remember thinking on the day I turned 60, May 10, 2021, “This is going to be the best year of my life.” I couldn’t have been more wrong. Within weeks of feeling that swell of optimism about my future, I began experiencing a series of odd, and, seemingly unrelated symptoms leading to my eventual...
A Timely Compendium for the Era of Precision Oncology
The pace at which precision oncology has evolved over the past 2 decades, from the early promise of the Human Genome Project to the clinical reality of CAR T-cell therapy, antibody drug conjugates, and AI-assisted decision support, has made it increasingly difficult for even the most engaged...
Four Ways AI Is Transforming Patient Care—and What Lies Ahead
During her Presidential address at the 2025 ASCO Annual Meeting, Robin T. Zon, MD, FACP, FASCO, assessed how artificial intelligence (AI) is driving knowledge into action in the field of oncology, and acknowledged that “we are now at the crossroads of long-imagined possibilities and actionable...
Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health
Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, and many countries have now implemented CT-based screening programs. In a perspective recently...
Uniting Science, Practice, and Purpose for Better Cancer Care
Growing up as an American in Mexico City, I couldn’t have grasped how that upbringing would eventually shape my professional identity. While a career in oncology was far from my mind then, that cross-cultural foundation deeply influenced my approach to medicine and my leadership as ASCO’s 62nd...
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years,1 it varies widely for some cancers among AYAs who are diagnosed with cancer. For example, AYAs have substantially worse ...
GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Real-world data suggest that GLP-1 receptor agonists (RAs) may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findings to be presented at the 2026 ASCO Annual Meeting (Abstract 3143). GLP-1 receptor expression ...
Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer
Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results of a two-arm pilot randomized trial presented at the 2026 ASCO Annual Meeting (Abstract 5517).1...
Case 2: Follicular Lymphoma With Relapse After Rituximab Monotherapy
This is Part 2 of Relapsed/Refractory Follicular Lymphoma: Choosing the Right Regimen for the Right Patient, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Loretta Nastoupil, Carla Casulo, and Kami Maddocks discuss the...
Case 1: Early Relapsed Follicular Lymphoma
This is Part 1 of Relapsed/Refractory Follicular Lymphoma: Choosing the Right Regimen for the Right Patient, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Loretta Nastoupil, Carla Casulo, and Kami Maddocks discuss the...
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
Researchers have developed a novel diagnostics tool to detect gene fusions in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with greater sensitivity than standard detection algorithms, according to findings from a study published in The Journal of Molecular Diagnostics. The researchers...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
How Conquering Cancer Is a Team Effort
After finishing her academic studies, Dr. Mittendorf enlisted in the U.S. Air Force—an experience that would propel her into the field of oncology. “My second day on active duty was September 11, 2001,” said Dr. Mittendorf. “I was an attending surgeon at Walter Reed Army Medical Center (now called...
Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Miszczyk et al found that local therapies alone are associated with “reasonable efficacy” in select patients with locally radiorecurrent prostate cancer. Study Details A literature search through May 2025 was performed to identify...
Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer
A new urine test performed better than prostate specific antigen (PSA)-based testing and magnetic resonance imaging (MRI) for monitoring patients with low-risk prostate cancer on active surveillance. Use of the test to determine the need for repeat “monitoring” biopsies would have avoided up to 64% ...
National Academy of Medicine Recognizes 100 Newly Elected Members
Overview of Member Election Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that acknowledges individuals who have made major...
Could AI Be Licensed to Practice Oncology?
Is artificial intelligence (AI) poised to practice medicine? It may be already. Earlier this year, the state of Utah allowed Doctronic, a health technology company using AI to make clinical decisions autonomously, to renew prescriptions for patients who request the service. Although Utah’s pilot...
Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures
Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occurring in low- and middle-income countries.1 Delays in obtaining an accurate diagnosis,...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
De-escalation, Recovery, and Robotic Surgery in Breast Cancer Care
At the American Society of Breast Surgeons (ASBrS) 27th Annual Meeting, investigators presented new findings on breast cancer surgery, postoperative recovery, and radiation treatment planning. Among the many sessions, several studies were presented during a media briefing earlier this month and are ...
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy plasma miR-371a-3p (miR-371), a...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
Breast Density Reduction: Endoxifen vs Tamoxifen
Low doses of the investigational agent endoxifen reduced breast density to the same extent as the standard treatment tamoxifen, with fewer adverse events, according to results from the KARISMA study, a proof-of-principle, dose-determining, double-blinded, randomized, placebo-controlled trial. These ...
AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans
In a landmark study published in Gut, Mukherjee et al developed and validated the Radiomics-based Early Detection Model (REDMOD), an automated artificial intelligence (AI) framework that identifies subtle, preclinical imaging signatures of pancreatic ductal adenocarcinoma on routine computed...
On-Treatment PSA and Overall Survival in Prostate Cancer
In a post hoc analysis reported in The Lancet Oncology, Kayani et al found that on-treatment prostate-specific antigen (PSA) level was associated with overall survival in patients with metastatic or very high-risk nonmetastatic prostate adenocarcinoma from five phase III trials in the STAMPEDE...
